Fate Therapeutics (FATE) stock price, revenue, and financials

Fate Therapeutics market cap is $5.4 b, and annual revenue was $31.43 m in FY 2020

$5.4 B

FATE Mkt cap, 12-Nov-2021

$11.1 M

Fate Therapeutics Revenue Q1, 2021
Fate Therapeutics Net income (Q1, 2021)-45.1 M
Fate Therapeutics EBIT (Q1, 2021)-46.2 M
Fate Therapeutics Cash, 31-Mar-2021106.4 M
Fate Therapeutics EV5.4 B
Get notified regarding key financial metrics and revenue changes at Fate TherapeuticsLearn more
Banner background

Fate Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

971.0k971.0k2.4m2.4m4.4m4.1m4.7m10.7m31.4m

Revenue growth, %

(81%)150%

R&D expense

12.0m16.4m19.9m26.5m34.4m56.0m87.8m125.6m

General and administrative expense

6.6m8.5m10.4m9.9m11.9m15.8m23.6m33.9m

Operating expense total

18.6m24.9m30.2m36.4m46.2m71.8m111.4m159.5m

EBIT

(17.7m)(24.9m)(24.9m)(27.8m)(27.8m)(32.0m)(42.1m)(67.1m)(100.7m)(128.1m)

EBIT margin, %

(1820%)(2565%)(1143%)(1143%)(726%)(1026%)(1415%)(943%)(407%)

Interest expense

549.0k2.2m

Interest income

6.0k2.0k2.0k10.0k10.0k138.0k559.0k2.2m4.3m2.4m

Net Income

(20.9m)(25.9m)(25.9m)(30.0m)(30.0m)(33.5m)(43.0m)(66.6m)(98.1m)(173.4m)

Fate Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

54.0m49.1m64.8m88.6m89.0m190.5m99.8m167.3m

Accounts Receivable

500.0k5.5m

Prepaid Expenses

615.0k771.0k843.0k1.6m3.7m5.7m5.9m

Inventories

1.2m

Current Assets

54.7m49.9m65.7m93.3m102.6m205.2m227.1m494.3m

PP&E

810.0k1.2m2.2m1.6m2.6m5.1m11.4m32.3m

Total Assets

55.6m51.2m68.0m95.0m105.3m213.0m302.3m622.5m

Accounts Payable

682.0k645.0k996.0k934.0k1.7m4.2m5.8m6.3m

Short-term debt

1.7m1.5m7.6m2.4m3.4m

Current Liabilities

4.6m4.6m13.4m15.2m11.0m27.3m27.8m85.6m

Long-term debt

18.1m10.7m14.8m12.4m25.2m93.9m

Total Debt

19.6m14.8m14.9m25.2m97.3m

Common Stock

20.0k21.0k29.0k53.0k65.0k76.0k88.0k

Preferred Stock

3.0k3.0k3.0k3.0k

Additional Paid-in Capital

137.3m140.7m180.4m295.9m445.8m628.2m941.2m

Retained Earnings

(112.4m)(142.4m)(175.8m)(218.8m)(285.4m)(383.5m)(556.9m)

Total Equity

50.8m28.3m38.0m73.2m77.2m160.5m244.8m384.4m

Financial Leverage

1.1 x1.8 x1.8 x1.3 x1.4 x1.3 x1.2 x1.6 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

19.1m47.9m42.0m45.5m42.3m81.2m72.9m39.5m35.9m37.1m40.6m31.1m43.2m32.9m36.2m183.2m183.0m71.4m249.6m83.4m433.1m349.1m106.4m

Accounts Receivable

846.0k500.0k500.0k500.0k1.7m3.2m6.9m

Prepaid Expenses

304.0k382.0k233.0k94.0k443.0k395.0k482.0k955.0k1.2m780.0k1.1m848.0k825.0k1.5m2.0m2.2m2.9m3.2m2.8m5.0m5.1m4.7m7.2m

Current Assets

19.4m48.3m42.2m45.6m42.8m81.6m74.2m56.6m47.1m47.4m83.4m71.9m70.0m90.6m80.0m213.9m186.4m165.2m305.6m208.2m540.2m496.8m804.3m

PP&E

789.0k1.3m1.2m1.2m1.5m1.8m2.1m2.0m1.9m1.8m1.7m1.9m2.5m2.6m2.9m3.8m8.4m9.2m9.7m11.9m15.9m20.7m48.0m

Total Assets

23.0m49.6m43.6m47.0m44.5m83.5m76.4m58.7m49.2m49.3m85.3m74.0m72.7m93.4m83.2m220.0m220.9m199.9m340.2m321.9m653.6m626.4m1.0b

Accounts Payable

3.7m1.3m980.0k1.2m1.3m1.5m1.3m2.0m2.0m1.2m2.5m1.2m2.2m2.2m3.5m5.2m5.4m5.4m5.7m5.2m13.6m3.7m9.0m

Short-term debt

2.0m1.2m746.0k611.0k3.3m5.2m6.5m7.7m7.9m8.0m7.6m758.0k2.0m3.3m3.9m5.4m13.9m1.9m2.4m2.3m4.4m

Current Liabilities

9.5m4.4m3.8m3.9m6.4m11.3m12.6m13.9m14.3m14.7m16.9m8.1m9.7m12.6m16.3m22.7m29.1m29.4m40.6m24.9m45.3m54.2m94.6m

Long-term debt

250.0k9.4m16.4m14.5m12.6m8.7m6.7m4.6m1.1m6.7m14.8m14.1m12.8m11.6m37.5m35.6m25.7m73.8m78.7m83.2m106.5m

Total Debt

2.2m1.2m746.0k9.4m16.4m14.5m12.6m8.7m6.7m4.6m1.1m6.7m14.8m14.1m12.8m11.6m11.0m41.0m39.6m75.7m81.0m85.5m110.9m

Common Stock

1.0k20.0k21.0k21.0k21.0k29.0k29.0k29.0k29.0k34.0k41.0k41.0k41.0k53.0k53.0k65.0k65.0k65.0k75.0k76.0k87.0k87.0k94.0k

Preferred Stock

3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k3.0k

Additional Paid-in Capital

14.4m138.6m139.2m139.7m141.5m179.1m179.9m181.4m182.3m193.2m249.8m250.8m252.0m297.9m304.4m443.2m450.9m456.0m623.2m636.1m918.5m927.8m1.4b

Retained Earnings

(99.6m)(106.2m)(120.3m)(128.1m)(134.9m)(150.8m)(159.2m)(167.9m)(186.0m)(195.6m)(206.3m)(232.9m)(252.6m)(269.4m)(305.2m)(328.6m)(355.2m)(417.1m)(445.1m)(503.8m)(602.0m)

Total Equity

(66.4m)45.2m39.6m33.6m21.3m51.1m45.0m30.7m23.1m25.4m63.9m55.2m45.7m65.0m51.8m173.9m145.8m127.5m268.0m219.2m474.1m424.4m790.1m

Debt to Equity Ratio

0.3 x0.8 x0.3 x0.3 x0.3 x0.3 x0.2 x0 x0.1 x0.3 x0.2 x0.2 x0.1 x0.1 x

Debt to Assets Ratio

0.2 x0.4 x0.2 x0.2 x0.1 x0.1 x0.1 x0 x0.1 x0.2 x0.2 x0.2 x0.1 x0 x

Financial Leverage

-0.3 x1.1 x1.1 x1.4 x2.1 x1.6 x1.7 x1.9 x2.1 x1.9 x1.3 x1.3 x1.6 x1.4 x1.6 x1.3 x1.5 x1.6 x1.3 x1.5 x1.4 x1.5 x1.3 x

Fate Therapeutics Cash Flow

Annual

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(15.2m)(7.0m)(13.0m)(19.6m)(7.9m)(15.7m)(22.5m)(8.4m)(16.8m)(25.5m)(10.1m)(19.8m)(30.5m)(14.1m)(33.8m)(50.6m)(19.8m)(43.2m)(69.8m)(33.5m)(61.6m)(120.3m)(45.1m)

Depreciation and Amortization

442.0k123.0k256.0k371.0k128.0k290.0k477.0k227.0k460.0k678.0k206.0k437.0k681.0k286.0k567.0k877.0k440.0k983.0k1.6m705.0k1.5m2.2m959.0k

Accounts Receivable

(846.0k)(500.0k)(500.0k)500.0k500.0k(1.7m)(3.2m)(1.4m)

Accounts Payable

1.4m43.0k8.0k236.0k269.0k856.0k759.0k790.0k1.2m1.3m1.7m1.1m957.0k673.0k2.7m3.9m(1.3m)(893.0k)2.8m(3.3m)4.8m(2.6m)6.9m

Cash From Operating Activities

(10.8m)(5.3m)(10.7m)(16.3m)(6.4m)(4.3m)(11.4m)(7.3m)(14.8m)(22.3m)(7.5m)(16.3m)(26.2m)(12.6m)(24.1m)(27.6m)(17.5m)(37.8m)(57.6m)(26.7m)12.2m(18.6m)(27.1m)

Purchases of PP&E

(94.0k)(398.0k)(424.0k)(611.0k)(452.0k)(665.0k)(1.3m)(178.0k)(384.0k)(417.0k)(155.0k)(566.0k)(928.0k)(184.0k)(462.0k)(1.2m)(1.7m)(3.5m)(4.8m)(1.1m)(1.7m)(2.7m)(4.0m)

Cash From Investing Activities

(88.0k)(398.0k)(424.0k)(611.0k)(452.0k)(665.0k)(1.3m)(16.3m)(10.5m)(10.1m)(38.4m)(37.0m)(23.4m)(43.8m)(30.1m)(16.8m)8.8m(83.2m)(46.9m)23.8m59.1m5.0m(471.9m)

Long-term Borrowings

(1.5m)(500.0k)(1.0m)(1.7m)(611.0k)(1.9m)(3.8m)(5.7m)(2.0m)(4.1m)(10.8m)(1.0m)

Cash From Financing Activities

20.9m(502.0k)(856.0k)8.4m75.0k37.0m36.5m(1.7m)(3.6m)4.7m(2.2m)(4.2m)4.2m355.0k1.5m138.9m1.3m1.9m163.7m1.5m277.0m277.9m438.1m

Net Change in Cash

10.0m(6.2m)(12.0m)(8.5m)(6.8m)32.1m23.8m(25.3m)(28.9m)(27.7m)(48.0m)(52.7m)94.4m(7.5m)(119.1m)59.1m(1.4m)348.3m264.3m(60.9m)

Interest Paid

309.0k626.0k938.0k

Fate Therapeutics Ratios

USDQ3, 2013

Financial Leverage

-0.3 x

Fate Therapeutics Employee Rating

4.221 votes
Culture & Values
4.5
Work/Life Balance
3.5
Senior Management
4.6
Salary & Benefits
3.6
Career Opportunities
4.2
Source